Irati Beltrán Hernández1,2, Rene Rompen3, Raffaella Rossin4, Katerina T Xenaki1, Eugene A Katrukha1, Klaas Nicolay3, Paul van Bergen En Henegouwen1, Holger Grüll5,6,7, Sabrina Oliveira8,9. 1. Division of Cell Biology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands. 2. Pharmaceutics, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. 3. Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. 4. Department of Minimally Invasive Healthcare, Philips Research Laboratories, Eindhoven, The Netherlands. 5. Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. holger.gruell@uk-koeln.de. 6. Department of Minimally Invasive Healthcare, Philips Research Laboratories, Eindhoven, The Netherlands. holger.gruell@uk-koeln.de. 7. Department of Diagnostic and Interventional Radiology, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. holger.gruell@uk-koeln.de. 8. Division of Cell Biology, Department of Biology, Faculty of Science, Utrecht University, Utrecht, The Netherlands. s.oliveira@uu.nl. 9. Pharmaceutics, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. s.oliveira@uu.nl.
Abstract
PURPOSE: Recent studies have shown rapid accumulation of nanobodies (NBs) in tumors and fast clearance of the unbound fraction, making NBs exceptional tracers for cancer imaging. In this study, we investigate the combination of in vitro imaging of tumor spheroids, in vivo dual-isotope single-photon emission computed tomography (SPECT), and ex vivo autoradiographic analysis of tumors to efficiently, and with few mice, assess the tumor uptake and distribution of different NBs. PROCEDURES: The irrelevant NB R2 (16 kDa) and the EGFR-targeted NBs 7D12 (16 kDa) and 7D12-R2 (32 kDa) were investigated. Confocal microscopy was used to study the penetration of the NBs into A431 tumor spheroids over time, using the anti-EGFR monoclonal antibody (mAb) cetuximab (150 kDa) as a reference. Dual-isotope [111In]DOTA-NB/[177Lu]DOTA-NB SPECT was used for longitudinal imaging of multiple tracers in the same animal bearing A431 tumor xenografts. Tumor sections were analyzed using autoradiography. RESULTS: No binding of the irrelevant NB was observed in spheroids, whereas for the specific tracers an increase in the spheroid's covered area was observed over time. The NB 7D12 saturated the spheroid earlier than the larger, 7D12-R2. Even slower penetration was observed for the large mAb. In vivo, the tumor uptake of 7D12 was 19-fold higher than R2 after co-injection in the same animal, and 2.5-fold higher than 7D12-R2 when co-injected. 7D12-R2 was mainly localized at the rim of tumors, while 7D12 was found to be more evenly distributed. CONCLUSIONS: This study demonstrates that the combination of imaging of tumor spheroids, dual-isotope SPECT, and autoradiography of tumors is effective in comparing tumor uptake and distribution of different NBs. Results were in agreement with published data, highlighting the value of monomeric NBs for tumor imaging, and re-enforcing the value of these techniques to accurately assess the most optimal format for tumor imaging. This combination of techniques requires a lower number of animals to obtain significant data and can accelerate the design of novel tracers.
PURPOSE: Recent studies have shown rapid accumulation of nanobodies (NBs) in tumors and fast clearance of the unbound fraction, making NBs exceptional tracers for cancer imaging. In this study, we investigate the combination of in vitro imaging of tumor spheroids, in vivo dual-isotope single-photon emission computed tomography (SPECT), and ex vivo autoradiographic analysis of tumors to efficiently, and with few mice, assess the tumor uptake and distribution of different NBs. PROCEDURES: The irrelevant NB R2 (16 kDa) and the EGFR-targeted NBs 7D12 (16 kDa) and 7D12-R2 (32 kDa) were investigated. Confocal microscopy was used to study the penetration of the NBs into A431 tumor spheroids over time, using the anti-EGFR monoclonal antibody (mAb) cetuximab (150 kDa) as a reference. Dual-isotope [111In]DOTA-NB/[177Lu]DOTA-NB SPECT was used for longitudinal imaging of multiple tracers in the same animal bearing A431 tumor xenografts. Tumor sections were analyzed using autoradiography. RESULTS: No binding of the irrelevant NB was observed in spheroids, whereas for the specific tracers an increase in the spheroid's covered area was observed over time. The NB 7D12 saturated the spheroid earlier than the larger, 7D12-R2. Even slower penetration was observed for the large mAb. In vivo, the tumor uptake of 7D12 was 19-fold higher than R2 after co-injection in the same animal, and 2.5-fold higher than 7D12-R2 when co-injected. 7D12-R2 was mainly localized at the rim of tumors, while 7D12 was found to be more evenly distributed. CONCLUSIONS: This study demonstrates that the combination of imaging of tumor spheroids, dual-isotope SPECT, and autoradiography of tumors is effective in comparing tumor uptake and distribution of different NBs. Results were in agreement with published data, highlighting the value of monomeric NBs for tumor imaging, and re-enforcing the value of these techniques to accurately assess the most optimal format for tumor imaging. This combination of techniques requires a lower number of animals to obtain significant data and can accelerate the design of novel tracers.
Authors: Peter Bannas; Alexander Lenz; Valentin Kunick; Lennart Well; William Fumey; Björn Rissiek; Friedrich Haag; Joanna Schmid; Kerstin Schütze; Anna Eichhoff; Martin Trepel; Gerhard Adam; Harald Ittrich; Friedrich Koch-Nolte Journal: Contrast Media Mol Imaging Date: 2015-04-27 Impact factor: 3.161
Authors: Marta Kijanka; Frank-Jan Warnders; Mohamed El Khattabi; Marjolijn Lub-de Hooge; Gooitzen M van Dam; Vasilis Ntziachristos; Liesbeth de Vries; Sabrina Oliveira; Paul M P van Bergen En Henegouwen Journal: Eur J Nucl Med Mol Imaging Date: 2013-06-19 Impact factor: 9.236
Authors: Sabrina Oliveira; Raimond Heukers; Jirawas Sornkom; Robbert J Kok; Paul M P van Bergen En Henegouwen Journal: J Control Release Date: 2013-09-11 Impact factor: 9.776
Authors: Timo W M De Groof; Vida Mashayekhi; Tian Shu Fan; Nick D Bergkamp; Javier Sastre Toraño; Jeffrey R van Senten; Raimond Heukers; Martine J Smit; Sabrina Oliveira Journal: Mol Pharm Date: 2019-06-19 Impact factor: 4.939
Authors: Reinier Damman; Alessandra Lucini Paioni; Katerina T Xenaki; Irati Beltrán Hernández; Paul M P van Bergen En Henegouwen; Marc Baldus Journal: J Biomol NMR Date: 2020-06-19 Impact factor: 2.835
Authors: Emma Renard; Estel Collado Camps; Coline Canovas; Annemarie Kip; Martin Gotthardt; Mark Rijpkema; Franck Denat; Victor Goncalves; Sanne A M van Lith Journal: Cancers (Basel) Date: 2021-01-23 Impact factor: 6.639
Authors: Katerina T Xenaki; Bram Dorrestijn; Joey A Muns; Kevin Adamzek; Sofia Doulkeridou; HendrikJan Houthoff; Sabrina Oliveira; Paul Mp van Bergen En Henegouwen Journal: Theranostics Date: 2021-03-13 Impact factor: 11.556
Authors: Marion M Deken; Marta M Kijanka; Irati Beltrán Hernández; Maxime D Slooter; Henriette S de Bruijn; Paul J van Diest; Paul M P van Bergen En Henegouwen; Clemens W G M Lowik; Dominic J Robinson; Alexander L Vahrmeijer; Sabrina Oliveira Journal: J Control Release Date: 2020-04-21 Impact factor: 9.776
Authors: Estel Collado Camps; Sanne A M van Lith; Cathelijne Frielink; Jordi Lankhof; Ingrid Dijkgraaf; Martin Gotthardt; Roland Brock Journal: Pharmaceuticals (Basel) Date: 2021-06-23
Authors: Tobias Stemler; Caroline Hoffmann; Ina M Hierlmeier; Stephan Maus; Elmar Krause; Samer Ezziddin; Gregor Jung; Mark D Bartholomä Journal: ChemMedChem Date: 2021-05-24 Impact factor: 3.466